Search

Your search keyword '"Odou P"' showing total 135 results
Start Over Author "Odou P" Search Limiters Peer Reviewed
135 results on '"Odou P"'

1. Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial

Author

Moreau, Caroline, Odou, Pascal, Labreuche, Julien, Demailly, Alexandre, Touzet, Gustavo, Reyns, Nicolas, Gouges, Bastien, Duhamel, Alain, Barthelemy, Christine, Lannoy, Damien, Carta, Natacha, Palas, Benjamin, Vasseur, Michèle, Marchand, Felix, Ollivier, Thomas, Leclercq, Céline, Potey, Camille, Ouk, Thavarak, Baigne, Simon, Dujardin, Kathy, Carton, Louise, Rolland, Anne Sophie, Devedjian, Jean Christophe, Foutel, Véronique, Deplanque, Dominique, Fisichella, Matthieu, and Devos, David

Published
2025
Full Text
View/download PDF

3. Premières journées francophones des utilisateurs de système d’aide à la décision en pharmacie clinique : retour d’expériences et perspectives

Author

Robert, L., Rousselière, C., Beuscart, J.-B., Gautier, S., Delporte, L., Lafci, G., Gerard, E., Négrier, L., Mary, A., Johns, E., Payen, A., Ducommun, R., Ferret, L., Voirol, P., Skalafouris, C., Ade, M., Potier, A., Dufay, E., Beney, J., Frery, Pauline, Drouot, Sylvain, Feutry, F., Corny, J., Odou, P., and Décaudin, B.

Published
2023
Full Text
View/download PDF

29. The Efficacy of Positive Psychology Interventions to Increase Well-Being and the Role of Mental Imagery Ability

Author

Odou, Natasha and Vella-Brodrick, Dianne A.

Abstract

This study examined the effects of mental imagery ability (MIA) on the efficacy of two positive psychology interventions (PPIs) to enhance well-being. Participants (N = 210) were randomly assigned to either: Three Good Things (TGT), Best Possible Selves (BPS), or a control group and completed well-being questionnaires pre and post intervention. ANCOVA results partially supported the hypothesis that the interventions would significantly increase well-being (measured by the WEMWBS, PA and NA) compared to the control group. Correlations partially supported the prediction that greater effort and motivation towards the PPI would relate to greater increases in well-being. MIA was not found to influence the efficacy of the PPIs, hence, refuting the final hypothesis that participants with high MIA would report greater post-intervention increases in well-being than participants with low MIA (measured by imagery vividness and controllability scales). Well-being was positively correlated with MIA suggesting that improving MIA might facilitate an increase in well-being regardless of PPI use.

Published
2013
Full Text
View/download PDF

39. The role of tranexamic acid in the management of postpartum haemorrhage.

Author

Bouthors, Anne-Sophie, Gilliot, Sixtine, Sentilhes, Loïc, Hennart, Benjamin, Jeanpierre, Emmanuelle, Deneux-Tharaux, Catherine, Lebuffe, Gilles, and Odou, Pascal

Abstract

In the last decades, tranexamic acid (TXA) has emerged as an essential tool in blood loss management in obstetrics. TXA prophylaxis for postpartum haemorrhage (PPH) has been studied in double-blind, placebo-controlled, randomized clinical trials (RCTs). Given the small observed preventive effect, the systematic use of TXA for vaginal and/or caesarean deliveries remains controversial. The result of a pharmacokinetic modelling suggests that relative to intravenous administration, intramuscular administration may be an equally effective alternative route for preventing PPH and may enable access to this drug in low-resource countries. Prophylaxis is currently studied in high-risk populations, such as women with prepartum anaemia or placenta previa. TXA effectively reduces blood loss and PPH-related morbidity and mortality during active PPH, as demonstrated by high-grade evidence from large RCTs. The drug has a good safety profile: in most cases, only mild gastrointestinal or visual adverse events may be observed. TXA use does not increase the risk of serious adverse events, such as venous or arterial thromboembolism, seizures, or acute kidney injury. The TRACES in vivo analysis of biomarkers of TXA's antifibrinolytic effect have suggested that a dose of at least 1 g is required for the treatment of PPH. The TRACES pharmacokinetic model suggests that because TXA can be lost in the haemorrhaged blood, a second dose should be administered if the PPH continues or if severe coagulopathy occurs. Future pharmacodynamic analyses will focus on the appropriateness of TXA dosing regimens with regard to the intensity of fibrinolysis in catastrophic obstetric events. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. A prospective, single-centre study of the feasibility of the use of augmented reality for improving the safety and traceability of injectable investigational cancer drug compounding

Author

Arthur Lecoutre, Michele Vasseur, Justin Courtin, Slim Hammadi, Bertrand Decaudin, and Odou Pascal

Subjects
Chemotherapy, Clinical trials, Preparation, Quality control, Augmented reality, User satisfaction, Science (General), Q1-390, Social sciences (General), H1-99
Abstract

The compounding of injectable cancer drugs for clinical trials often requires specific procedures, with limited access to the starting materials and especially the active compound. These characteristics prevent the application of qualitative or quantitative analyses and quality control techniques. Hence, for some very complex compounding operations, double visual inspection is considered to be less reliable, more time-consuming and more human-resource-intensive than other methods. The compounding team at Lille University Hospital (Lille, France) has equipped one of its preparation areas with a new device: augmented reality (AR) eyewear connected to an oncology drug management system, as a support tool for compounding and quality control. The tool has been tested, adapted and improved within the unit and is now used for investigational drug compounding on a routine basis. In a prospective, single-centre study, we evaluated the feasibility of the implementation of this novel AR approach for the compounding of injectable investigational cancer drugs. During the 6-month study period, 564 clinical trial compounding operations were performed with the AR eyewear. The proportion of poor-quality photos taken with the AR eyewear fell over time, as users became more familiar with the tool. A user satisfaction survey highlighted a very high level of uptake and a wish to broaden the scope of the compounding performed with AR support. The AR eyewear constitutes an innovative, cost-effective tool that increased the level of safety without disrupting the unit's operating procedures. The tool's flexibility enabled its integration into a variety of working environments. The various improvements now being developed should help to further boost the added value of this novel device.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results